Donation

The International Myeloma Foundation (IMF) presents its 2024 Research Grant awards.
Senior Grant Recipient
Mark Bustoros, MD
Mark Bustoros, MD
Weill Medical College
New York, NY, USA
Characterizing the Role and Targeting of the histone methyltransferase Setd2in Multiple Myeloma

The overall goal of this proposal is to determine the role of Setd2 in multiple myeloma pathogenesis and the effects of targeting it on cell survival and proliferation. Our central hypothesis is that SETD2 is an essential gene for myeloma pathogenesis through maintaining genomic stability and transcription of essential genes in tumor cells and has a synthetic lethal effect in the t(4;14) subtype.

This is based on our preliminary data showing that SETD2 is frequently overexpressed and mutated in newly diagnosed and asymptomatic MM patients, and genetic and chemical perturbation of SETD2 is cytotoxic to myeloma cells and their proliferation.

Funded by the Inland Empire Virtual/In-Person Walk for Myeloma Miracles and Miles for Myeloma 5K Run/Walk.

Junior Grant Recipients
Martin Gazvoda, PhD
Martin Gazvoda, PhD
University of Ljubljana
Ljubljana, Slovenia
Boron-rich antibodies for synergistic targeted therapy with boron neutron capture therapy (BNCT) in multiple myeloma data

Although boron neutron capture therapy (BNCT) has been described as a nearly ideal treatment for cancer, it is not accepted as a treatment option in the clinic. Despite tremendous efforts, the major challenge to date has been to selectively deliver boron to target cells.

Building on our proof of principle that proteins can be selectively enriched with boron, we aim to enable targeted BNCT for the treatment of multiple myeloma by preparing boron-rich antibodies.

The synergistic effect of demonstrated therapeutic profile of antibodies combined with localized lethal alpha radiation at myeloma sites could overcome the treatment challenges, e.g., solid malignancies.

Funded by Laughs for Life.

Alireza Gholipour, PhD
Alireza Gholipour, PhD
Massachusetts General Hospital
Boston, MA, USA
Advancing spinal stability in multiple myeloma: a predictive biomechanical simulation approach

This study aims to develop a patient-specific predictive biomechanical simulation model for spinal stability in multiple myeloma patients.

The first aim is to investigate biomechanical factors contributing to spinal instability in multiple myeloma using advanced simulation techniques. The second aim is to develop a patient-specific predictive model incorporating disease-related factors, identifying patients at higher risk of spinal instability.

The final aim is to validate and refine the predictive model through clinical evaluation,comparing predictions with actual outcomes.

This study contributes to personalized medicine for managing spinal health in multiple myeloma, improving patient outcomes.

Funded by Miracles for Myeloma 5K Walk/Run.

Give Where Most Needed